Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on EUROCELL PLC. We currently have 2 research reports from 1 professional analysts.
|20Mar17 14:44||RNS||Holding(s) in Company|
|20Mar17 14:42||RNS||Holding(s) in Company|
|17Mar17 07:00||RNS||Director/PDMR Shareholding|
|17Mar17 07:00||RNS||Result of Placing|
|16Mar17 16:36||RNS||Proposed Placing|
|10Mar17 07:00||RNS||Confirmation of dividend payment date|
|08Mar17 07:00||RNS||Final Results|
Frequency of research reports
Research reports on
Moving up a gear
16 Mar 17
New management is driving an enhanced commercial focus. This was not wholly apparent in headline FY16 results, but was evident in strategic actions taken which are set to accelerate in FY17. Our sense is that the business will respond quickly to these initiatives. Eurocell’s share price has started to respond to the new corporate messaging and the delivery of profitable revenue growth is likely to attract further support.
Growing in branded building products
05 Nov 15
Eurocell floated on the London Stock Exchange earlier this year with a growth agenda driven by a number of internal initiatives. Its vertically integrated model brings enhanced margin opportunities balanced between manufacturing and distribution activities. H115 results demonstrated good profit progress consistent with management’s full year expectations.
N+1 Singer - Morning Song 21-03-2017
21 Mar 17
accesso Technology (ACSO LN) Full year results in line, but key trading months still ahead | Augean (AUG LN) Double digit growth in ’16, good start to ‘17 | Earthport (EPO LN) Interims show continued top line strength | Goals Soccer Centres (GOAL LN) Good momentum under new team. It’s now all about delivery | IQE (IQE LN) FY’16 results prompt further upgrades | Microsaic Systems (MSYS LN) Challenges in 2016, strategy remains in place | mporium Group (MPM LN) Funds raised to help execute strategy | RhythmOne (RTHM LN) Dawn of the independents | ScS Group (SCS LN) Strong progress on key growth initiatives albeit comps now toughen | Sinclair Pharma (SPH LN) FY results: EBITDA ahead, Instalift™ gaining pace | Vectura Group (VEC LN) FY (9-month) results
N+1 Singer - Augean - Double digit growth in ’16, good start to ‘17
21 Mar 17
Augean reported another year of double digit growth for 2016, with profits in line with our forecasts. Sales grew by 21% excluding landfill tax, while adjusted PBT grew by 18% to £7.1m before amortisation of acquired intangibles. DPS was increased by 54% to 1.0p, 25% ahead of our estimate. The business units made further strategic progress, with revenues from their top 20 customers increasing from 42% to 43% of the total, of which 88% was under contract or a framework agreement, increasing forward visibility. There has been an encouraging start to 2017 and management is confident of delivering another year of profits growth. The shares trade on undemanding single digit multiples, offering good value.